EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology

Michel J Vos iD, Mark R Postma iD, Eef G Lentjes, Lisanne Habich-Reijntjes, Dylan Kelly, Anneke Muller Kobold, Gianni Bocca iD, Melanie M van der Klauw, André P van Beek iD, Ido P Kema, Martijn van Faassen iD

European Journal of Endocrinology · 04.03.2026 · 194 (3) · 347-356

DOI: 10.1093/ejendo/lvag040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Endocrinology, online erschienen am 27.02.2026. Verfasst von Michel J Vos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor I, Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Endocrinology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, Dutch Ministry of Health, Welfare and Sport, University Medical Center Groningen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accurate interpretation of insulin-like growth factor-1 (IGF1) requires both analytically robust measurement and appropriate reference data. Most available IGF1 normative datasets are based on ligand-binding assays (LBA), limiting their applicability to liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods that provide higher analytical specificity.

Objective

To evaluate the clinical performance of an in-house developed LC-MS/MS IGF1 assay in combination with a method-matched normative dataset derived from the Dutch Lifelines cohort, and to compare it with a commonly used LBA.

Methods

Paired IGF1 results (n = 2057) were obtained using LC-MS/MS and the IDS iSYS LBA. Standard deviation scores (SDS) were calculated using assay-specific normative datasets. Agreement was assessed by regression, Bland-Altman, and weighted Cohen's κ analyses. Clinical validity was evaluated by comparing extreme SDS values with diagnostic categories adjudicated by endocrinologists.

Results

The LC-MS/MS method showed a proportional bias of −27% versus IDS iSYS and yielded symmetrically distributed SDS around zero, whereas IDS iSYS results were positively skewed. Categorical agreement was fair (κ = 0.39). LC-MS/MS-derived SDS corresponded more closely with clinical diagnoses across adult and pediatric groups, including acromegaly, growth hormone (GH) deficiency, and GH replacement therapy.

Conclusions

Our LC-MS/MS IGF1 assay integrated with its own population-based normative dataset demonstrated superior alignment with clinical assessment compared with LBA results. In our setting, this method provides a clinically reliable benchmark for IGF1 interpretation and may serve as a reference for IGF1 harmonization and broader adoption of the Lifelines normative dataset in routine endocrinology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Like Growth Factor ITandem Mass SpectrometryLiquid Chromatography-Mass SpectrometryEndocrinologyHumansFemaleAdultMaleReference ValuesMiddle AgedAdolescentChildAgedYoung AdultChromatography, LiquidCohort StudiesAcromegaly

Stichwörter der Autor:innen

IGF1LC-MS/MSacromegalygrowth hormone deficiencymass spectrometry

Substanzen

Insulin-Like Growth Factor IIGF1 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Central Diagnostic Laboratory, University of Utrecht, Utrecht Medical Center, Utrecht, The Netherlands.
  • Division of Endocrinology, Department of Paediatrics, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

ORCID-Profile: Michel J Vos, Mark R Postma, Gianni Bocca, André P van Beek, Martijn van Faassen

Förderung

  • Pfizer
  • Dutch Ministry of Health, Welfare and Sport
  • University Medical Center Groningen
  • University of Groningen

Zitieren

APA

Vos, M. J., Postma, M. R., Lentjes, E. G., Habich-Reijntjes, L., Kelly, D., Muller Kobold, A., Bocca, G., van der Klauw, M. M., van Beek, A. P., Kema, I. P., & van Faassen, M. (2026). Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology. European Journal of Endocrinology, 194(3), 347-356. https://doi.org/10.1093/ejendo/lvag040

Vancouver

Vos MJ, Postma MR, Lentjes EG, Habich-Reijntjes L, Kelly D, Muller Kobold A, et al. Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology. European Journal of Endocrinology. 2026;194(3):347-356. doi:10.1093/ejendo/lvag040

BibTeX
@article{Vos2026,
  author = {Vos, Michel J and Postma, Mark R and Lentjes, Eef G and Habich-Reijntjes, Lisanne and Kelly, Dylan and Muller Kobold, Anneke and Bocca, Gianni and van der Klauw, Melanie M and van Beek, André P and Kema, Ido P and van Faassen, Martijn},
  title = {Clinical performance of an IGF1 LC-MS/MS assay and associated normative dataset in routine endocrinology},
  journal = {European Journal of Endocrinology},
  year = {2026},
  volume = {194},
  number = {3},
  pages = {347--356},
  doi = {10.1093/ejendo/lvag040}
}
Kostenlos starten →